---
title: "KLRA.US (KLRA.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KLRA.US/news.md"
symbol: "KLRA.US"
name: "KLRA.US"
parent: "https://longbridge.com/en/quote/KLRA.US.md"
datetime: "2026-05-30T21:59:53.574Z"
locales:
  - [en](https://longbridge.com/en/quote/KLRA.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KLRA.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KLRA.US/news.md)
---

# KLRA.US (KLRA.US) — Related News

### [Jefferies Sticks to Their Buy Rating for Kailera Therapeutics, Inc. (KLRA)](https://longbridge.com/en/news/287949963.md)
*2026-05-28T15:55:33.000Z*
> Jefferies analyst Roger Song has maintained a Buy rating for Kailera Therapeutics, Inc. (KLRA) with a price target of $4

### [Hengrui's Phase III clinical trial succeeds, adding another player to the GLP-1 billion-dollar market](https://longbridge.com/en/news/287754057.md)
*2026-05-27T10:19:12.000Z*
> Hengrui Pharma and Kailera Therapeutics announced positive results from the Phase III clinical trial of their oral GLP-1

### [TD Cowen Reaffirms Their Buy Rating on Kailera Therapeutics, Inc. (KLRA)](https://longbridge.com/en/news/287719655.md)
*2026-05-27T05:15:13.000Z*
> TD Cowen analyst Yaron Werber has reaffirmed a Buy rating on Kailera Therapeutics, Inc. (KLRA), with shares closing at U

### [Kailera Therapeutics | 8-K: FY2026 Q1 Revenue: USD 0](https://longbridge.com/en/news/287704079.md)
*2026-05-27T02:24:14.000Z*
### [Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates | KLRA Stock News](https://longbridge.com/en/news/287673757.md)
*2026-05-26T12:02:00.000Z*
> Kailera Therapeutics reported its Q1 2026 financial results, highlighting significant progress in its obesity pipeline, 

### [This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst](https://longbridge.com/en/news/286304929.md)
*2026-05-13T18:43:40.000Z*
> William Blair has initiated coverage on Kailera Therapeutics (NASDAQ:KLRA) with an Outperform rating, highlighting its c

### [BCPE Perseus Investor Takes Activist Stake at Kailera Therapeutics with 20.3% Stake](https://longbridge.com/en/news/283906549.md)
*2026-04-23T23:36:00.000Z*
> BCPE Perseus Investor, LP has acquired a 20.3% stake in Kailera Therapeutics, Inc., which includes pre-IPO preferred sha